Nasal Allergy Treatment Market

Nasal Allergy Treatment Market Snapshot

The global nasal allergy treatment market enjoys a valuation of USD 6.6 Billion in 2022, and it is further projected to expand at a CAGR of 6.7% over the forecasted years. According to a recent study by Future Market Insights, allergic rhinitis by disease is leading the market with a share of about 65.8% in the year 2022, within the global market.

Market Outlook

Data Points	Market Insights
Market Value 2022	USD 6.6 Billion
Market Value 2033	USD 13.3 Billion
CAGR 2023 to 2033	6.7%
Market Share of Top 5 Countries	62.1%
Key Market Players	Merck KGaA, Johnson & Johnson, Allergopharma, Sanofi SA, McNeil Consumer Healthcare, Genentech Inc., GlaxoSmithKline PLC, Leti Pharma, Alerpharma S.A, Allergan, Inc., Meda Pharmaceuticals, Inc, Novartis International AG, Bausch Health Companies Inc., Allergopharma , ALK Abello, Stallergenes, Greer, Allergy Therapeutics, Aimmune Therapeutics, Biomay AG, HAL Allergy Group, Bayer, AstraZeneca

Nasal allergy, or allergic rhinitis (AR), a non-infectious inflammatory disease of the nasal mucosa following exposure to inhaled allergens in atopic patients, is mediated by IgE and involves a number of immune cells and cytokines. The currently available treatment options have increased due to a growing number of manufacturers identifying allergy as an area of interest and also with the help of a research and development team they are bringing in new innovative treatment and therapy options to the market. Although we are in the second wave of allergic diseases there is still a persistent amount of the population who suffer from nasal allergies.

Sales Analysis of Nasal Allergy Treatment Market from 2018 to 2022 Vs Market Outlook for 2023 to 2033.

The global sales of the market are anticipated to rise at a CAGR of 6.7% between 2023 and 2033, owing to the rising prevalence of allergic diseases.

The global market holds around 32.6% share of the overall global allergy treatment market with a value of around USD 20.2 Billion, in 2022.

The market is expanding as a result increase in the patient pool suffering from allergies. In fact, it is anticipated that the need for nasal allergy treatments would rise in the coming years due to the patient’s comfort and ease as it reduces inflammation, and remove congestion. The incidence rate and prevalence rate of allergic rhinitis are growing rapidly owing to which the demand for available treatments is expected to increase over the forecast period.

Some of the most popular therapies for nasal allergies are antihistamines, decongestants, nasal corticosteroids, allergen immunotherapy, and leukotriene receptor antagonists. Antihistamines rule the market, as it is one of the highly prescribed and adopted drugs for the treatment of allergies with or without prescription.

Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around USD 13.3 billion during the year 2033.

What are the Key Opportunities for the Manufacturers Operating in the Global Market?

Globally, the prevalence of hay fever/allergic rhinitis was registered at ~35%, which is gaining the attraction of manufacturers to develop a specific treatment for this indication. This creates an enormous opportunity for the manufacturer to explore the nasal allergy treatment market. The life science industry has set foot into the pharmaceutical industry giving rise to multiple biopharma companies that have proven technology and advanced treatment options that are exclusive and received approval, this gives healthcare specialists to rely upon these new treatment options.

For instance, the main method for treating people with sensitivities to aeroallergens is subcutaneous immunotherapy (SCIT). Subcutaneous immunotherapy (SCIT), a revolutionary treatment for allergic illnesses, reduces discomfort while modifying allergic disease by concentrating on the underlying immunological mechanism. In numerous well-controlled clinical trials, its effectiveness and safety have been proven in the treatment of allergies, allergic rhinitis/rhinoconjunctivitis, asthma, and hypersensitivity to stinging insects.

Overall, it is anticipated that the market for nasal allergy treatments will rise over the coming years as more research and development are put into creating fresh, efficient treatment choices.

What are the Factors Restraining Demand within the Global Market?

The market is experiencing a decline due to the adverse effects associated with allergy shots and tablets.

• For instance, more than 1.5% of the patients administering oral air experience adverse effects such as respiratory, gastrointestinal, or skin-related disorders.

Along with that, patients can experience minor effects such as redness or swelling at the injection site or effects on the entire body or particular body system. Along with that, rarely, a serious systemic reaction called anaphylaxis can develop.

In a few cases, people can experience systematic reactions such as hives, nasal congestion, watery eyes, and sneezing. More severe reactions may include wheezing or chest tightness and throat swelling. Rarely, allergy treatments can cause anaphylaxis, a potentially fatal reaction. It may result in low blood pressure and respiratory difficulties. An allergy shot can sometimes cause a significant reaction in a person. The majority of these can happen within 30 minutes of the injection.

The side effects associated with the treatment may hinder the market growth.

Country-wise Insights

What Makes the USA a Large Market for Nasal Allergy Treatment?

The USA dominates the North American region with a total market share of around 92.4% in 2022 and is expected to continue to maintain consistent growth over the entire projected period with a CAGR of 5.8%. The main drivers of nasal allergy prevalence in the United States include environmental factors such as air pollution, climate change, and exposure to allergens such as pollen and dust mites.

Allergies are the sixth most common chronic ailment in the United States, according to the American College of Allergy, Asthma & Immunology, with a cost of more than USD 18 billion annually. Each year, more than 50 million Americans experience allergic reactions. The frequency of AR was 19.9%, according to a recent large retrospective cohort study by Frontiers Media S.A. in the year 2023. According to the National Health Interview Survey done by the Centers for Disease Control and Prevention in 2018, 19.2 million adults in the US had hay fever (allergic rhinitis) in the previous 12 months.

Since the prevalence is high the manufacturer finds it lucrative to regulate in such a market, therefore this factor influences the nasal allergy treatment market in the most favorable manner in the USA market.

What is the Outlook of China in the Nasal Allergy Treatment Market?

China has a market share of 65.8% in the East Asia nasal allergy treatment market in 2022. Disease progression can be retarded by taking precautions such as diagnostic tests which include the provocation test, specific IgG4 test, tIgE test, and multiple other specific tests that can lead to successful treatment outcomes. China is focusing on improving its diagnosis to pace up into the global market.

For the prevention and treatment of allergic disorders, allergen detection is essential. Although China's technology is now lacking, many of the diagnostic gaps will soon be filled thanks to the development of new microparticle- and array-based methods.

To assist allergists and laboratory personnel in improving the diagnostic standard and directing the treatment of allergic illnesses for the benefit of patients and the market as a whole, this consensus summarizes the existing in vivo and in vitro diagnostic procedures for allergens.

What is the Scenario of Germany within the Nasal Allergy Treatment Market Space?

Germany holds a market share of 29.8% in 2022 in the European nasal allergy treatment market, owing to the presence of many established players in European countries.

Bencard Allergie, the German division of Allergy Therapeutics in the United Kingdom, which creates allergy vaccinations, was referenced by Labiotech UG in June 2022. The first allergoids for allergen-specific immunotherapies were marketed by a German business. With the use of virus-like particles, Allergy Therapeutics, and its affiliates are developing a novel method for allergy immunotherapy. Bencard appears to be in a strong position despite its opponents. According to a recent report from Allergy Therapeutics, Bencard contributes 60% of the company's revenues in Germany, which is where sales are growing the fastest.

Germany is strengthening its manufacturing and development of novel drugs which will positively grow the market in the future.

What Makes India a Highly Lucrative Market for Nasal Allergy Treatment?

India holds a share of around 48.6% in the South Asia market in 2022.

India has one of the highest levels of pollution, which is largely brought on by the use of mosquito coils and incense sticks indoors, and by outdoor, biomass, fossil fuels, and vehicle exhausts. According to Elsevier Inc., there are an estimated 37.5 million instances of asthma in India, and recent studies have indicated that the frequency of allergic rhinitis and asthma would rise in 2020.

Although India's prevalence rates are generally lower than those of high-income nations, there are still several million instances of the disease overall, according to various estimates. Indian manufacturers must therefore increase their supply of treatment drugs in order to handle such a sizable patient population.

Category-wise Insights

Which Nasal Allergy Treatment Disease is driving the Market Growth?

Allergic rhinitis is expected to give high growth at a CAGR of 6.4% between 2023 and 2033. As per American Academy of Allergy Asthma and Immunology, 2022, allergic rhinitis affects almost 10-30% of the population worldwide. Additionally, sensitization to foreign proteins present in the environment affects upto 40% of the global population. In the geriatric population, rhinitis is less commonly allergic in nature. Hence the prevalence contributes to the global shares.

Which form is favored within the Global Market?

Tablets/Capsules are mostly favored by patients suffering from allergies. It has a market share of 37.1% in the global market in 2022.

The most popular sort of pill is a tablet. They encourage market growth since they are an affordable, secure, and efficient method of delivering oral medications. Tablets and capsules are frequently used by makers and formulators of drug products as a dosage form that is affordable.

Among OTC and Prescription which holds the dominant market share of the Global Market?

OTC has a market share of 76.3% in the global market in 2022. OTC medications are easier for customers to obtain because they are readily available and may be bought without a prescription. People aren't obliged to wait for medications to be filled or schedule appointments with doctors, which saves time and money. Because OTC drugs are typically less expensive than prescription drugs, more people can afford them.

Which is the preferred route of administration?

Oral route of administration is mostly preferred by patients. It has a market share of 36.6% in the global market in 2022.

Patients can take oral medications at home without the need for medical supervision because they are simple to administer. Patients who need long-term treatment for chronic diseases would especially benefit from this. Drugs used orally are frequently less expensive than medications taken orally or intravenously, which require more specialized equipment and medical supervision.

How Antihistamines is ahead of other treatments in Global Market?

Antihistamines have a market share of 46.0% in the global market in 2022. Since histamine, a substance secreted by the body in response to an allergen is blocked by antihistamines, they are frequently given for allergies. Sneezing, itching, and runny nose are examples of common allergic reaction symptoms that are brought on by histamine. A variety of allergic reactions, including as hay fever, allergic rhinitis, and hives, can be successfully treated with them.

Which Distribution Channel Benefits the Most from the Sales within the Market?

Hospital pharmacies hold a market share of 35.9% during the year 2022. The main locations where easily accessible licensed and approved medicine is found are hospitals. Hospital pharmacies may greatly enhance patient care by working together with doctors, nurses, and pharmacy teams to supply the appropriate medications and supplies in accordance with treatment procedures. The assurance of better patient outcomes aids hospitals in exceeding patient satisfaction targets. The segment is anticipated to grow at a profitable pace over the forecast period because of the comprehensive care provided in hospital settings.

Competitive Landscape

Increase in number of pipeline products and approval by the regulatory bodies, along with merger and acquisition by key players in different regions, are key differentiating strategies that nasal allergy treatment manufacturers are adopting.

• In Aug 2018, two products from HAL Allergy Group received marketing clearance in Germany. They include SUBLIVAC® Birch 40.000 AUN/ml and SUBLIVAC® Trees 40.000 AUN/ml.
• Nestle Health Science announced in August 2020 that it will purchase the food allergy product line of Aimmune Therapeutics, Inc. The agreement should be finalised by the fourth quarter of 2020.

Similarly, recent developments related to companies manufacturing nasal allergy treatment drugs have been tracked by the team at Future Market Insights. These are available in the full report.

Report Scope as per Nasal Allergy Treatment Industry Analysis

Attribute	Details
Forecast Period	2018 to 2022
Historical Data Available for	2023 to 2033
Market Analysis	USD Million for Value
Key Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; and the Middle East & Africa
Key Countries Covered	The USA, Canada, Brazil, Mexico, Argentina, the United kingdom, Germany, Italy, Russia, Spain, France, Benelux, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa and South Africa
Key Market Segments Covered	Disease Type, Form, Prescription Type, Route of Administration, Treatment, Distribution Channel and Region
Key Companies Profiled	Merck KGaA; Johnson & Johnson; Allergopharma; Sanofi SA; McNeil Consumer Healthcare,; Genentech Inc.; GlaxoSmithKline PLC; Leti Pharma,; Alerpharma S.A; Allergan, Inc.; Meda Pharmaceuticals, Inc; Novartis International AG; Bausch Health Companies Inc.; Allergopharma; ALK Abello; Stallergenes Greer; Allergy Therapeutics; Aimmune Therapeutics; Biomay AG; HAL Allergy Group; Bayer; AstraZeneca
Report Coverage	Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Pricing	Available upon Request

Key Market Segments Covered in the Nasal Allergy Treatment Industry Research

By Disease Type:

• Allergic Rhinitis
• Seasonal Allergic Rhinitis
• Perennial Allergic Rhinitis
• Non-Allergic Rhinitis
• Infectious Rhinitis

By Form:

• Tablets/Capsules
• Liquid
• Creams & Lotions
• Drops
• Spray

By Prescription Type:

• OTC
• Prescription based

By Route of Administration:

• Oral
• Intranasal
• Sublingual
• Sub Cutaneous
• Intravenous

By Treatment:

• Antihistamines
• Decongestants
• Nasal Corticosteroids
• Allergen Immunotherapy
• Leukotriene Receptor Antagonists

By Distribution Channel:

• Hospital Pharmacies
• Supermarkets/Hypermarkets
• Online Pharmacies
• Retail Pharmacies
• Speciality Clinics
• Others

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• The Middle East and Africa (MEA)

Frequently Asked Questions

What is the Growth Potential of the Nasal Allergy Treatment Market?

The growth potential of the power nibbler market is 6.7% through 2033.

What Limits the Growth Potential of the Nasal Allergy Treatment Market?

Adverse effect of tablets is likely to limit market growth.

What is the North America’s Significant CAGR in 2023?

North America is likely to capture a CAGR of 5.8% in 2023.

Which Country is Fastest-growing in the Nasal Allergy Treatment Market in 2023?

The United States is estimated as the fastest-growing country.

Which Disease Type is Leading the Nasal Allergy Treatment Market in 2023?

Allergic rhinitis segment is leading the global market in 2023.